You are here

Antonio C. Wolff, MD

Professor of Oncology
Member, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
on behalf of the Translational Breast Cancer Research Consortium

Current Research

Goal: To accelerate new treatments to benefit patients through focused clinical trials

Impact: TBCRC trials continue to provide insight into the development of more effective and individualized treatments for various subtypes of breast cancer. Funding from BCRF remains critical to bring together scientific resources and researchers to develop new strategies to reduce the burden of breast cancer. Results from these trials provide valuable insight that will guide personalized treatment for various subtypes of breast cancer.

What’s next: Ongoing teleconference calls with TBCRC working groups, in person meetings and conference presentations are planned for the upcoming year.

Full Research Summary

Research area: Advancing treatments to patients in the shortest time possible through focused clinical trials and identifying markers to improve clinical trial stratification and patient outcomes.

Impact: The current understanding of breast cancer as a complex disease extending beyond the most common clinical subtypes (hormone receptor-positive, HER2-positive, and triple-negative) requires the design of smaller niche trials that are rich in correlative studies to advance treatments to patients in the quickest possible time.  These studies typically require extensive biospecimen collection, often require specialized imaging, enroll fewer patients across a larger number of centers, and require coordinated planning among lab researchers, clinical trialists, biostatisticians, research coordinators, and advocates. As such, in 2006, several academic leaders banded together to establish the Translational Breast Cancer Research Consortium (TBCRC).

Current research: The TBCRC, under the leadership of Dr. Wolff, is comprised of 19 major clinical centers and over 300 clinical, laboratory, bioinformatics and administrative support staff

What they’ve accomplished so far: Over 330 patients were enrolled on TBCRC studies between June 2018 and June 2019, bringing the tally to over 5000 patients enrolled on TBCRC studies since the inception of the consortium. As of May 2019, thirty-six TBCRC trials have been completed, thirteen trials remain active, and three trials are pending activation. This year, results from seven TBCRC clinical trials have been presented at major medical conferences; five trials have published findings in leading medical journals.

What’s next: The TBCRC continues to hold regular teleconferences among its five core working groups (WGs): Correlative Science WG, the Triple Negative WG, the HER2 Resistance WG, the Endocrine Resistance WG, and the Locoregional Disease WG. The WGs are designed to foster clinical trial concept development in a collegial, nurturing environment and to enhance cross-institutional collaborations. A Patient Advocacy working group works closely with each clinical working group to ensure that the patient voice is represented in clinical trial design. Each year, the TBCRC holds two face to face meetings to discuss new clinical design concepts, trial results and provide feedback to trialists to improve clinical trial design or patient recruitment.


Dr. Antonio Wolff is a Professor of Oncology at Johns Hopkins University (JHU) and a member of the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA). He received his medical degree at the Universidade Federal do Rio de Janeiro in Brazil and trained in medical oncology at Johns Hopkins. He is an Associate Editor of the Journal of Clinical Oncology, Chair of the ECOG-ACRIN Breast Cancer Committee, and Chief Operating Officer for the Translational Breast Cancer Research Consortium (TBCRC). He is a Fellow of the American Society of Clinical Oncology (FASCO) and past Chair of its Clinical Practice Guidelines Committee. His research interests include new treatment strategies, the development and implementation of prognostic and predictive biomarkers (tissue, blood, and imaging) in clinical practice, and on how to improve the survivorship experience of breast cancer patients and their caregivers. He is a Susan G. Komen Scholar, recipient of a Cancer Clinical Investigator Team Leadership Award from the US National Cancer Institute, and has been recognized since 2017 by Clarivate Analytics (Thomson Reuters) as one of the world’s most highly cited researchers (top 1% in clinical medicine). He maintains an active clinical practice dedicated to the care of patients with breast cancer and was inducted in 2018 as a member of the JHU Miller Coulson Academy of Clinical Excellence. In 2018, Dr. Wolff was recognized as one of 125 Living the Hopkins Mission Honorees, who were selected for their outstanding dedication to the institution’s core values of excellence and discovery, leadership and integrity, diversity and inclusion, and respect and collegiality, as part of the 125th anniversary celebration of the JHU School of Medicine.

Grid Researcher Headshot - Wolff A

BCRF Investigator Since


Area(s) of Focus